

117TH CONGRESS
1ST SESSION

S. 1133

To direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program to support or conduct research on valvular heart disease, and for other purposes.

IN THE SENATE OF THE UNITED STATES

APRIL 15, 2021

Mr. McCONNELL (for himself and Ms. SINEMA) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program to support or conduct research on valvular heart disease, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Cardiovascular Ad-
5 vances in Research and Opportunities Legacy Act”.

1 **SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-**
2 **SEARCH.**

3 Subpart 2 of part C of title IV of the Public Health
4 Service Act (42 U.S.C. 285b et seq.) is amended by insert-
5 ing after section 424C the following:

6 **“SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-**
7 **SEARCH.**

8 “(a) IN GENERAL.—The Director of the National In-
9 stitutes of Health, in consultation with the Director of the
10 Institute, shall support or conduct research regarding val-
11 vular heart disease.

12 “(b) SUPPORT GUIDELINES.—The distribution of
13 funding authorized in subsection (a) may be used to pur-
14 sue any of the following outcomes:

15 “(1) Using precision medicine and advanced
16 technological imaging to generate data on individ-
17 uals with valvular heart disease.

18 “(2) Identifying and developing a cohort of in-
19 dividuals with valvular heart disease and available
20 data.

21 “(3) Corroborating data generated through clin-
22 ical trials to develop a prediction model to distin-
23 guish individuals at high risk for sudden cardiac ar-
24 rest or sudden cardiac death from valvular heart dis-
25 ease.

1 “(4) Other outcomes needed to acquire nec-
2 essary data on valvular heart disease.

3 “(c) MITRAL VALVE PROLAPSE WORKSHOP.—Not
4 later than one year after the date of enactment of this
5 section, the Director of the Institute shall convene a work-
6 shop composed of subject matter experts and stakeholders
7 to identify research needs and opportunities to develop
8 prescriptive guidelines for treatment of individuals with
9 mitral valve prolapse.

10 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the
11 purpose of carrying out this section, there is authorized
12 to be appropriated \$20,000,000 for each of fiscal years
13 2022 through 2026.”.

14 **SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL**
15 **AND PREVENTION.**

16 Part J of title III of the Public Health Service Act
17 (42 U.S.C. 280b et seq.) is amended by inserting after
18 section 393D the following section:

19 **“SEC. 393E. PREVENTION OF SUDDEN CARDIAC DEATH AS A**
20 **RESULT OF VALVULAR HEART DISEASE.**

21 “(a) IN GENERAL.—The Secretary, acting through
22 the Director of the Centers for Disease Control and Pre-
23 vention, may carry out projects to increase education,
24 awareness, or diagnosis of valvular heart disease and to
25 reduce the incidence of sudden cardiac death caused by

1 valvular heart disease. Such projects may be carried out
 2 by the Secretary directly or through awards of grants or
 3 contracts to public or nonprofit private entities. The Sec-
 4 retary may directly (or through such awards) provide tech-
 5 nical assistance with respect to the planning, development,
 6 and operation of such projects.

7 “(b) CERTAIN ACTIVITIES.—Projects carried out
 8 under subsection (a) may include—

9 “(1) the implementation of public information
 10 and education programs for—

11 “(A) the prevention of sudden cardiac
 12 death from valvular heart disease;

13 “(B) broadening the awareness of the pub-
 14 lic concerning the risk factors for, the symp-
 15 toms of, and the public health consequences of,
 16 valvular heart disease; and

17 “(C) increasing screening, detection, and
 18 diagnosis of valvular heart disease; and

19 “(2) surveillance of out-of-hospital cardiac ar-
 20 rests to improve patient outcomes.

21 “(c) GRANT PRIORITIZATION.—The Secretary may,
 22 in awarding grants or entering into contracts pursuant to
 23 subsection (a), give priority to entities seeking to carry
 24 out projects that target populations most impacted by val-
 25 vular heart disease.

1 “(d) COORDINATION OF ACTIVITIES.—The Secretary
2 shall ensure that activities under this section are coordi-
3 nated, as appropriate, with other agencies of the Public
4 Health Service that carry out activities regarding valvular
5 heart disease.

6 “(e) BEST PRACTICES.—The Secretary, acting
7 through the Director of the Centers for Disease Control
8 and Prevention, shall—

9 “(1) collect and analyze the findings of research
10 conducted with respect to valvular heart disease; and

11 “(2) taking into account such findings, publish
12 on the website of the Centers for Disease Control
13 and Prevention best practices for physicians and
14 other health care providers who provide care to indi-
15 viduals with valvular heart disease.

16 “(f) AUTHORIZATION OF APPROPRIATIONS.—For the
17 purpose of carrying out this section, there is authorized
18 to be appropriated such sums as may be necessary for
19 each of fiscal years 2022 through 2026.”.

○